<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-226 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-226</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-226</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-10.html">extraction-schema-10</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of autoimmune diseases in thymoma patients, including prevalence rates, proposed mechanisms, immunological findings, and clinical characteristics that explain the connection between thymomas and autoimmunity.</div>
                <p><strong>Paper ID:</strong> paper-1fddc9998706a5072f84b8677b5de62c962d3595</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/1fddc9998706a5072f84b8677b5de62c962d3595" target="_blank">Randomized Trial of Thymectomy in Myasthenia Gravis.</a></p>
                <p><strong>Paper Venue:</strong> New England Journal of Medicine</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e226.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e226.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of autoimmune diseases in thymoma patients, including prevalence rates, proposed mechanisms, immunological findings, and clinical characteristics that explain the connection between thymomas and autoimmunity.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MG</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Myasthenia gravis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An antibody-mediated autoimmune disorder of the neuromuscular junction characterized in this trial cohort by elevated circulating acetylcholine-receptor (AChR) antibodies and generalized fatigable weakness; the principal autoimmune disease discussed in relation to thymic pathology and thymectomy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Randomized Trial of Thymectomy in Myasthenia Gravis</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_name</strong></td>
                            <td>myasthenia gravis</td>
                        </tr>
                        <tr>
                            <td><strong>autoimmune_disease_prevalence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>thymoma_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>The paper emphasizes a central role of the thymus in the pathogenesis of myasthenia gravis: thymomas (when present) and thymic abnormalities (including thymic hyperplasia) are implicated in driving the autoimmune response that produces anti-AChR antibodies. The authors cite thymic pathology (thymoma or hyperplastic thymic tissue) as the anatomical/biologic substrate linking thymic disease to autoimmunity, motivating removal of thymic tissue (thymectomy).</td>
                        </tr>
                        <tr>
                            <td><strong>immunological_findings</strong></td>
                            <td>Enrolled patients had elevated circulating acetylcholine-receptor (AChR) antibodies (inclusion criterion); the paper also notes that up to ~70% of nonthymomatous MG patients have hyperplastic thymic changes (versus healthy persons). No additional primary-data immune profiling (e.g., T-cell repertoire, regulatory T cells) is reported in this trial manuscript.</td>
                        </tr>
                        <tr>
                            <td><strong>autoantibodies_present</strong></td>
                            <td>antiâ€“acetylcholine-receptor (AChR) antibodies</td>
                        </tr>
                        <tr>
                            <td><strong>timing_relative_to_thymoma</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>effect_of_thymectomy</strong></td>
                            <td>In this randomized trial of patients with nonthymomatous AChR-seropositive generalized myasthenia gravis, thymectomy (extended transsternal) plus prednisone produced better clinical outcomes over 3 years (lower time-weighted average QMG score by 2.85 points) and a lower time-weighted average alternate-day prednisone requirement (32 mg vs. 54 mg) compared with prednisone alone; the paper also states that thymectomy is considered mandatory when a thymoma is present to prevent further spread (clinical rationale rather than trial data).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_characteristics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>thymic_structure_abnormalities</strong></td>
                            <td>The manuscript reports that thymomas occur in ~10% of patients with myasthenia gravis and that up to ~70% of the remaining MG patients have hyperplastic thymic changes not seen in healthy persons; the paper also discusses ectopic thymic tissue as a surgical consideration (ectopic thymus can affect outcomes if left behind).</td>
                        </tr>
                        <tr>
                            <td><strong>t_cell_characteristics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_without_autoimmunity</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>control_comparison</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Randomized Trial of Thymectomy in Myasthenia Gravis.', 'publication_date_yy_mm': '2016-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Immunopathogenesis of myasthenia gravis <em>(Rating: 2)</em></li>
                <li>Myasthenia gravis <em>(Rating: 2)</em></li>
                <li>Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms <em>(Rating: 2)</em></li>
                <li>Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>